President Trump unveiled a groundbreaking executive order aimed at slashing U.S. prescription drug prices after a friend’s shocking discovery that the same weight-loss medication cost $1,300 in New York but only $88 in London.
At a Glance
- Trump’s executive order targets excessive U.S. drug pricing through “Most-Favored-Nation” pricing measures
- A personal anecdote about a friend paying $1,300 in New York versus $88 in London for the same medication sparked the initiative
- The order could potentially reduce American drug prices by 50-90%, according to Trump
- U.S. prescription drugs currently cost 2.78 times more than in 33 other countries, per a Rand report
- The plan establishes price targets and confronts foreign practices that unfairly impact U.S. drug costs
Personal Story Reveals Drug Pricing Disparities
President Trump revealed how a conversation with a wealthy friend illuminated the drastic difference in prescription drug prices between the United States and other countries. This friend had purchased the same weight-loss medication from identical manufacturing facilities but discovered an alarming price gap. The medication that cost $1,300 in New York was available for just $88 in London – a price difference of nearly 15 times for the identical product.
During a campaign event, Trump described his friend as “very smart” and “very rich,” noting that while his friend could afford the higher American prices, most Americans face significant financial hardship when purchasing necessary medications. This personal anecdote served as a compelling illustration of what data has long confirmed – Americans pay substantially more for prescription drugs than citizens of other developed nations.
Executive Order Details and Implementation
The executive order signed by Trump directs U.S. officials to implement several mechanisms aimed at lowering prescription drug prices. Central to the plan is establishing “price targets” for pharmaceutical manufacturers and allowing Americans to purchase medications at a “Most-Favored-Nation” price. This approach would prevent drug companies from charging American consumers substantially more than customers in other developed countries for identical products.
— Austin Campbell (@CampbellJAustin) May 3, 2025
The order also addresses the practices of foreign countries that Trump describes as “ruthless” in their negotiations with pharmaceutical companies. According to the administration, these nations secure favorable pricing while effectively forcing American consumers to subsidize drug research and development costs. By confronting these international pricing disparities, the order aims to level the playing field for American consumers.
According to President Trump: “He said, ‘You better, because this is crazy.’ He didn’t understand it, he didn’t understand why, and now he understands why, ’cause he watched our news conference this morning, holding his breath, but he watched the news conference”.
Potential Impact on American Consumers
According to Trump’s statements, the implementation of this executive order could result in dramatic reductions to U.S. prescription drug prices, potentially cutting costs by 50% to 90%. This would represent a transformative change for millions of Americans who currently struggle to afford necessary medications or who ration their prescriptions due to financial constraints.
The scale of the current pricing disparity is well-documented. A comprehensive Rand Corporation report found that prescription drug prices in the United States are, on average, 2.78 times higher than those in 33 other nations. For brand-name drugs, the gap is even more pronounced, with U.S. prices averaging 3.44 times higher than in comparison countries.
Trump attributed these price disparities to two primary factors: the significant political influence of pharmaceutical companies in Washington and the exploitation of U.S. market conditions by foreign countries. By directly addressing both issues, the executive order aims to substantially reduce the financial burden on American consumers while maintaining pharmaceutical innovation.
